Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy. more
Time Frame | GNTA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.6% | -0.94% | -2.6% |
1-Month Return | 2.24% | -5.08% | -1.08% |
3-Month Return | 32.35% | -10.62% | 3.45% |
6-Month Return | 46.62% | -6.18% | 8.57% |
1-Year Return | -3.9% | 1.98% | 24.3% |
3-Year Return | -58.67% | -0.93% | 25.58% |
5-Year Return | -55.48% | 33.84% | 84.07% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 1.77K | 5.08K | 6.03K | 41.58K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":4.26,"profit":true},{"date":"2021-12-31","value":12.23,"profit":true},{"date":"2022-12-31","value":14.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | (1.77K) | (5.08K) | (6.03K) | (41.58K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-177022,"profit":false},{"date":"2021-12-31","value":-508402,"profit":false},{"date":"2022-12-31","value":-602942,"profit":false},{"date":"2023-12-31","value":-4158200,"profit":false}] |
Gross Margin | - | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 4.62M | 5.59M | 5.54M | 11.04M | 11.73M | [{"date":"2019-12-31","value":39.41,"profit":true},{"date":"2020-12-31","value":47.65,"profit":true},{"date":"2021-12-31","value":47.19,"profit":true},{"date":"2022-12-31","value":94.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (4.62M) | (5.59M) | (5.69M) | (11.04M) | (11.73M) | [{"date":"2019-12-31","value":-462450200,"profit":false},{"date":"2020-12-31","value":-559022600,"profit":false},{"date":"2021-12-31","value":-568727300,"profit":false},{"date":"2022-12-31","value":-1104399200,"profit":false},{"date":"2023-12-31","value":-1173294200,"profit":false}] |
Total Non-Operating Income/Expense | 17.23K | (9.54K) | 146.22K | 2.60M | 396.74K | [{"date":"2019-12-31","value":0.66,"profit":true},{"date":"2020-12-31","value":-0.37,"profit":false},{"date":"2021-12-31","value":5.62,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":15.24,"profit":true}] |
Pre-Tax Income | (4.60M) | (5.59M) | (5.53M) | (8.48M) | (11.65M) | [{"date":"2019-12-31","value":-459772300,"profit":false},{"date":"2020-12-31","value":-559201400,"profit":false},{"date":"2021-12-31","value":-552933200,"profit":false},{"date":"2022-12-31","value":-847776300,"profit":false},{"date":"2023-12-31","value":-1164545500,"profit":false}] |
Income Taxes | 9.55K | 13.72K | 31.37K | (4.85M) | 4.00 | [{"date":"2019-12-31","value":30.45,"profit":true},{"date":"2020-12-31","value":43.73,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-15468.46,"profit":false},{"date":"2023-12-31","value":0.01,"profit":true}] |
Income After Taxes | (4.61M) | (5.61M) | (5.56M) | (3.62M) | (11.65M) | [{"date":"2019-12-31","value":-460727500,"profit":false},{"date":"2020-12-31","value":-560573400,"profit":false},{"date":"2021-12-31","value":-556070500,"profit":false},{"date":"2022-12-31","value":-362484400,"profit":false},{"date":"2023-12-31","value":-1164545900,"profit":false}] |
Income From Continuous Operations | (4.60M) | (5.59M) | (5.53M) | (8.48M) | (11.65M) | [{"date":"2019-12-31","value":-459772300,"profit":false},{"date":"2020-12-31","value":-559201400,"profit":false},{"date":"2021-12-31","value":-552933200,"profit":false},{"date":"2022-12-31","value":-847776300,"profit":false},{"date":"2023-12-31","value":-1164545500,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (4.61M) | (5.61M) | (5.56M) | (3.62M) | (11.65M) | [{"date":"2019-12-31","value":-460727500,"profit":false},{"date":"2020-12-31","value":-560573400,"profit":false},{"date":"2021-12-31","value":-556070500,"profit":false},{"date":"2022-12-31","value":-362484400,"profit":false},{"date":"2023-12-31","value":-1164545500,"profit":false}] |
EPS (Diluted) | (0.09) | (0.51) | - | - | - | [{"date":"2019-12-31","value":-9.47,"profit":false},{"date":"2020-12-31","value":-51.14,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
GNTA | |
---|---|
Cash Ratio | 10.82 |
Current Ratio | 12.25 |
Quick Ratio | 12.25 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GNTA | |
---|---|
ROA (LTM) | -25.83% |
ROE (LTM) | -42.89% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GNTA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GNTA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 5.19 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Genenta Science SpA ADR (GNTA) share price today is $4.8971
Yes, Indians can buy shares of Genenta Science SpA ADR (GNTA) on Vested. To buy Genenta Science SpA ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GNTA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Genenta Science SpA ADR (GNTA) via the Vested app. You can start investing in Genenta Science SpA ADR (GNTA) with a minimum investment of $1.
You can invest in shares of Genenta Science SpA ADR (GNTA) via Vested in three simple steps:
The 52-week high price of Genenta Science SpA ADR (GNTA) is $7.28. The 52-week low price of Genenta Science SpA ADR (GNTA) is $2.2.
The price-to-earnings (P/E) ratio of Genenta Science SpA ADR (GNTA) is
The price-to-book (P/B) ratio of Genenta Science SpA ADR (GNTA) is 5.19
The dividend yield of Genenta Science SpA ADR (GNTA) is 0.00%
The market capitalization of Genenta Science SpA ADR (GNTA) is $91.63M
The stock symbol (or ticker) of Genenta Science SpA ADR is GNTA